Your search for smoking cessation returned 23 results

Cigarette smoking may blunt the renal protective effects of drugs taken by patients with early chronic kidney disease.

According to new research published in The Journal of Infectious Diseases, smoking may actually decrease an HIV patient’s lifespan more than the virus itself.

At a joint meeting of the Food and Drug Administration (FDA)’s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, a majority vote recommended the removal of the boxed warning regarding serious neuropsychiatric adverse events from the Chantix (varenicline; Pfizer) labeling.

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for bupropion extended-release products.

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.

The USPSTF recommended against screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults.

Varenicline did not increase the rate of cardiovascular (CV) serious adverse events, according to data from a systematic review published in the Journal of the American Heart Association.

Researchers from the VA conducted a retrospective cohort study to compare the risk of mental health episodes requiring hospitalization or outpatient clinic visits associated with varenicline vs. nicotine patch use during the time prior to psychiatric boxed warnings.

Researchers found no significant differences in rates of smoking abstinence at 26 or 52 weeks following a 12-week treatment with a nicotine patch, varenicline, or combination nicotine replacement therapy (nicotine patch + nicotine lozenge [C-NRT]), in adults trying to quit smoking.

Researchers from Brown University reported that combining topiramate with psychological counseling reduced marijuana use among young smokers significantly more than counseling alone.